Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis.
Herpes simplex virus-1 (HSV-1) replication in cancer cells leads to their destruction (viral oncolysis) and has been under investigation as an experimental cancer therapy in clinical trials as single agents, and as combinations with chemotherapy. Cellular responses to chemotherapy modulate viral replication, but these interactions are poorly understood. To investigate the effect of chemotherapy on HSV-1 oncolysis, viral replication in cells exposed to 5-fluorouracil (5-FU), irinotecan (CPT-11), methotrexate (MTX) or a cytokine (tumor necrosis factor-α (TNF-α)) was examined. Exposure of colon and pancreatic cancer cells to 5-FU, CPT-11 or MTX in vitro significantly antagonizes both HSV-1 replication and lytic oncolysis. Nuclear factor-κB (NF-κB) activation is required for efficient viral replication, and experimental inhibition of this response with an IκBα dominant-negative repressor significantly antagonizes HSV-1 replication. Nonetheless, cells exposed to 5-FU, CPT-11, TNF-α or HSV-1 activate NF-κB. Cells exposed to MTX do not activate NF-κB, suggesting a possible role for NF-κB inhibition in the decreased viral replication observed following exposure to MTX. The role of eukaryotic initiation factor 2α (eIF-2α) dephosphorylation was examined; HSV-1-mediated eIF-2α dephosphorylation proceeds normally in HT29 cells exposed to 5-FU, CPT-11 or MTX. This report demonstrates that cellular responses to chemotherapeutic agents provide an unfavorable environment for HSV-1-mediated oncolysis, and these observations are relevant to the design of both preclinical and clinical studies of HSV-1 oncolysis.
Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114-2696, USA.
Y
Y
Kulu
H
H
Kawasaki
J M
JM
Donahue
H
H
Kasuya
J C
JC
Cusack
E W
EW
Choi
D K
DK
Kuruppu
B C
BC
Fuchs
K K
KK
Tanabe
D002166:Camptothecin / Q000031:analogs & derivatives / Q000494:pharmacology; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000494:pharmacology; D018259:Herpesvirus 1, Human / Q000235:genetics; D006801:Humans; D000077146:Irinotecan; D008727:Methotrexate / Q000494:pharmacology; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000235:genetics; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D015533:Transcriptional Activation / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014779:Virus Replication / Q000187:drug effects / Q000235:genetics
D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin; D008727:Methotrexate